Renal Cell Carcinoma as a Metabolic Disease: An Update on Main Pathways, Potential Biomarkers, and Therapeutic Targets
Nicola Antonio di Meo, Francesco Lasorsa, Monica Rutigliano, Davide Loizzo, Matteo Ferro, Alessandro Stella, Cinzia Bizzoca, Leonardo Vincenti, Savio Domenico Pandolfo, Riccardo Autorino, Felice Crocetto, E. Montanari, Marco Spilotros, Michele Battaglia, Pasquale Ditonno, Giuseppe Lucarelli
Abstract
Clear cell renal cell carcinoma (ccRCC) is the most frequent histological kidney cancer subtype. Over the last decade, significant progress has been made in identifying the genetic and metabolic alterations driving ccRCC development. In particular, an integrated approach using transcriptomics, metabolomics, and lipidomics has led to a better understanding of ccRCC as a metabolic disease. The metabolic profiling of this cancer could help define and predict its behavior in terms of aggressiveness, prognosis, and therapeutic responsiveness, and would be an innovative strategy for choosing the optimal therapy for a specific patient. This review article describes the current state-of-the-art in research on ccRCC metabolic pathways and potential therapeutic applications. In addition, the clinical implication of pharmacometabolomic intervention is analyzed, which represents a new field for novel stage-related and patient-tailored strategies according to the specific susceptibility to new classes of drugs.